For over a century, vaccines have been a pillar of medical care. Every vaccine developed to date is based upon the same fundamental principle: by teaching our immune systems to recognize a pathogen and destroy it, we can help protect our bodies from infectious diseases. We are building on this principle to develop vaccines against SARS-CoV-2, the coronavirus that causes COVID-19.
The adjuvanted recombinant protein vaccine candidate. In collaboration with the US BARDA, this vaccine candidate uses our recombinant protein manufacturing platform together with GSK’s pandemic adjuvant platform. It is progressing well in a phase 3 efficacy and safety trial. In parallel, we have expanded our research program to include a study of the vaccine as a potentially broadly protective booster dose. Recently published preclinical data showed that it has the potential to strongly boost immune responses following vaccination with many of the currently approved vaccines and against a broad range of variants.
The mRNA vaccine candidate. Positive interim results from a phase 1/2 study of this candidate confirmed the potential of recently acquired Translate Bio’s mRNA and lipid nanoparticle (LNP) platforms and support Sanofi’s mRNA strategy. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, we have decided not to pursue the development of our COVID-19 mRNA candidate into a phase 3 clinical study. We will focus our mRNA resources in our newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need.